色素性视网膜炎患者持续使用乙酰唑胺后囊样黄斑水肿的反弹
Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa.
作者信息
Apushkin Marsha A, Fishman Gerald A, Grover Sandeep, Janowicz Mark J
机构信息
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
出版信息
Retina. 2007 Oct;27(8):1112-8. doi: 10.1097/IAE.0b013e31805f6b79.
PURPOSE
To demonstrate the presence of a rebound effect with the use of acetazolamide for the treatment of cystoid macular edema (CME) in patients with retinitis pigmentosa (RP).
METHODS
Six patients with RP and cystic-appearing lesions in the macula demonstrated by fluorescein angiography and/or optical coherence tomography (OCT) were treated with an oral form of carbonic anhydrase inhibitor (acetazolamide [500 mg]) as a single daily dose.
RESULTS
All patients, treated with acetazolamide for a period of 3 weeks to 5 weeks, had initial improvement of macular edema demonstrated by OCT. However, extended use of acetazolamide, for at least 8 weeks to 12 weeks, resulted in recurrence (rebound) of CME in 3 of the 6 patients.
CONCLUSIONS
Results from our study suggest that rebound of CME with the continued use of acetazolamide observed by OCT may occur more frequently than previously appreciated.
目的
证明使用乙酰唑胺治疗色素性视网膜炎（RP）患者的黄斑囊样水肿（CME）时存在反跳效应。
方法
6例经荧光素血管造影和/或光学相干断层扫描（OCT）证实患有RP且黄斑区有囊性病变的患者，接受口服碳酸酐酶抑制剂（乙酰唑胺[500毫克]）治疗，每日单次给药。
结果
所有接受乙酰唑胺治疗3周-5周的患者，经OCT证实黄斑水肿均有初步改善。然而，6例患者中有3例在至少持续使用乙酰唑胺8周-12周后，出现了CME复发（反跳）。
结论
我们的研究结果表明，经OCT观察，持续使用乙酰唑胺导致CME反跳的情况可能比之前认为的更频繁。
Zotero 插件